An update on direct antiviral agents for the treatment of hepatitis C

World Health Organization. Global hepatitis report, 2017. Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 Cited 2021 Jan 12

AASLD. Recommendations for testing, managing, and treating hepatitis C available online at: https://www.hcvguidelines.org/[Accessed on 2021 Jan 12.

10.1016/j.jhep.2018.07.002

10.5812/hepatmon.28969v2

10.1101/cshperspect.a036855

10.3390/v11010030

10.1016/j.jhep.2014.06.031

10.1002/iub.1702

10.1128/AAC.04958-14

10.1073/pnas.0902693106

10.1016/j.biochi.2017.06.009

10.3748/wjg.v18.i43.6183

10.1111/nyas.12832

10.1080/17460441.2017.1322955

10.1016/j.jhep.2020.08.018

10.1177/1060028016668897

10.1056/NEJMoa1512610

Danvers MA, 2017, AASLD-IDSA

10.1056/NEJMoa1613512

10.1053/j.gastro.2017.03.047

FDA approves mavyret for hepatitis C. Silver spring, MD: FDA; 2017. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm August 3 [2020 Dec 22

COMMISSION IMPLEMENTING DECISION granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for “Maviret - glecaprevir/pibrentasvir”, a medicinal product for human use. Brussels, Belgium: European commission; 2017. Available from: http://ec.europa.eu/transparency/regdoc/?fuseaction=list&coteId=3&year=2017&number=5428&language=EN July 26 [Cited 2020 Dec 22.

10.1007/s40265-017-0817-y

10.1016/j.jhep.2017.03.039

10.1002/hep.29541

10.1016/j.cgh.2017.09.027

10.1056/NEJMoa1702417

10.1016/S1473-3099(17)30496-6

10.1016/S0168-8278(17)30444-0

A study to evaluate the efficacy and safety of ABT-493/ABT-530 in combination with sofosbuvir and ribavirin in participants with hepatitis C virus who did not respond to treatment in a previous AbbVie clinical study (MAGELLAN-3). Bethesda, MD: NIH; 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02939989 October 20 Cited 2020 Dec 22

A study to evaluate the efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1–6 infection and renal impairment (Expedition-5). Bethesda, MD: NIH; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT03069365?term=expedition5&cond=hcv&rank=1. March 3 Cited 2020 Dec 22

World Health Organization. Progress report on access to hepatitis C treatment. focus on overcoming barriers in low and middle income countries, march 2018. geneva, Switzerland: world health organization. (WHO/CDS/HIV/184) Licence: CC BY-NC-SA 30 IGO. 2018;

10.1002/hep.27641

10.1016/S2468-1253(17)30053-5

10.1002/cld.965

10.1111/liv.13626

10.1002/hep.31060

10.1080/14656566.2017.1419185

10.1038/s41581-018-0081-8

10.1056/NEJMoa1501315

10.1001/jama.2015.1373

Perillo RP, 2017, Hepatology, 66

Gilead Sciences, 2019, Harvoni (ledipasvir/sofosbuvir) [package insert]

Gilead Sciences, 2019, Sovaldi (sofosbuvir) [package insert]

AbbVie, 2019, Mavyret (glecaprevir/pibrentasvir) [package insert]

10.1097/MPG.0000000000002710

10.1053/j.gastro.2015.05.010

10.1016/S1473-3099(16)00052-9

10.1056/NEJMoa1512614

10.1016/S0618-8278(19)30413-X

10.1053/j.gastro.2018.03.022

10.1016/j.jhep.2016.07.039

10.1111/jvh.13039

10.1002/lt.24973

10.1016/j.jhep.2018.02.012

10.1016/j.jhep.2018.06.010

10.1002/hep.28926

10.1111/jvh.12877

10.1016/j.jhep.2018.05.039

10.1111/apt.15598

10.1016/j.jhep.2017.02.027

10.1016/j.jhep.2017.01.020

10.4254/wjh.v7.i17.2080

10.1007/s11938-018-0178-y

10.1093/cid/ciy585

10.1128/JCM.01985-20

10.1080/17425255.2016.1209484

10.1371/journal.pone.0165339

10.1016/j.jhep.2017.01.007

10.1038/s41598-018-27291-7

10.1128/AAC.02606-15

10.1007/s00535-018-1429-3

10.3851/IMP3177

10.1099/jgv.0.001091

10.1053/j.gastro.2017.11.007

10.1002/hep.29693

10.4103/jfmpc.jfmpc_943_19

10.3851/IMP3061

10.1002/cld.956

10.1093/ofid/ofaa040

10.4103/tcmj.tcmj_247_19

Lexi-Comp, 2019, Drug-drug interaction

Liverpool Uo. University of liverpool hepatitis drug interactions website. Available from: https://www.hep-druginteractions.org/. Last accessed on 2021 Jan 6

10.1007/s40262-019-00774-0

10.1016/j.compbiolchem.2014.11.001

10.1016/j.antiviral.2010.02.312

10.1007/0-387-25515-X_2

10.1038/nbt.3179